14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.0060 $169.56 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Feb 18, 2020 $0.443 $0.454 $0.430 $0.437 283 331
Feb 14, 2020 $0.443 $0.450 $0.422 $0.443 305 444
Feb 13, 2020 $0.456 $0.460 $0.413 $0.440 685 749
Feb 12, 2020 $0.476 $0.478 $0.450 $0.453 503 261
Feb 11, 2020 $0.500 $0.519 $0.460 $0.480 1 330 856
Feb 10, 2020 $0.450 $0.499 $0.440 $0.493 1 723 405
Feb 07, 2020 $0.432 $0.460 $0.431 $0.452 1 041 593
Feb 06, 2020 $0.432 $0.450 $0.414 $0.433 1 230 386
Feb 05, 2020 $0.412 $0.430 $0.407 $0.425 726 770
Feb 04, 2020 $0.408 $0.420 $0.400 $0.410 751 152
Feb 03, 2020 $0.437 $0.437 $0.405 $0.413 775 094
Jan 31, 2020 $0.412 $0.440 $0.400 $0.436 947 481
Jan 30, 2020 $0.450 $0.450 $0.350 $0.421 2 011 576
Jan 29, 2020 $0.550 $0.570 $0.455 $0.465 6 906 506
Jan 28, 2020 $0.396 $0.410 $0.396 $0.408 129 630
Jan 27, 2020 $0.403 $0.412 $0.380 $0.395 898 266
Jan 24, 2020 $0.430 $0.439 $0.400 $0.412 714 271
Jan 23, 2020 $0.441 $0.441 $0.420 $0.423 261 609
Jan 22, 2020 $0.446 $0.470 $0.418 $0.439 659 337
Jan 21, 2020 $0.430 $0.482 $0.430 $0.450 2 971 387
Jan 17, 2020 $0.423 $0.454 $0.420 $0.431 1 729 255
Jan 16, 2020 $0.417 $0.425 $0.410 $0.420 427 505
Jan 15, 2020 $0.408 $0.419 $0.400 $0.417 322 400
Jan 14, 2020 $0.395 $0.405 $0.393 $0.401 245 529
Jan 13, 2020 $0.403 $0.406 $0.392 $0.396 378 566
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT